Quipt Home Medical (QIPT) Q3 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $64 million, up 10% year-over-year, while Q3 2024 revenue was $64.0 million, up 6.1% year-over-year, with recurring revenue at 80%-82% of total.

• Adjusted EBITDA margin was 23.3% in Q2 and 22.3% in Q3, with Q3 Adjusted EBITDA at $14.2 million, a 2.7% increase year-over-year.

• Organic growth contributed $6.4 million (6.5%) in Q2 and 3% in Q3, with operational highlights including serving 270,087 unique patients in the nine months ended June 30, 2024, up 12.9% year-over-year.

• The company initiated a share repurchase program (NCIB) for up to 10% of public float after Q2 and maintained a focus on organic growth, cross-selling, and diabetes market expansion.

• Net loss for Q3 2024 was $1.7 million, or ($0.04) per diluted share, compared to a $1.0 million loss in Q3 2023.

Financial highlights

• Nine-month revenue rose to $193.3 million, up 21.4% year-over-year, with organic growth of $8.1 million (5%).

• Adjusted EBITDA for the nine months was $44.5 million, a 23.7% increase from the prior year period.

• Cash flow from operations for the nine months was $28.6 million, up from $27.3 million year-over-year.

• CapEx for the six months ended March 31 was $7.1 million (11.2% of revenue), down from $7.9 million year-over-year.

• Bad debt expense as a percentage of revenue increased to 5.0% in Q3 2024 from 4.0% in Q3 2023, mainly due to the Change Healthcare cyber incident.

Outlook and guidance

• Management targets 8%-10% annualized organic growth and expects consistent Adjusted EBITDA margin performance for the remainder of the year.

• Free cash flow is expected to be 6%-8% of revenue after CapEx and lease payments, before debt service and acquisitions.

• Anticipates a return to historical organic growth levels and continued steady demand for respiratory equipment.

• Cash collections are expected to normalize by June as claim backlogs from the Change Healthcare cyberattack are resolved.

• Focus remains on disciplined capital management, organic growth, and identifying synergistic acquisition opportunities.